Continued analyst endorsement underscores confidence in shareholder value and growth potential
London (UK), September 2025 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology company targeting aberrant mitochondrial metabolism in cancer, announced that Sphene Equity Research has reaffirmed its “Buy” recommendation on Vidac Pharma’s shares in its latest analyst report.
The updated report reflects continued confidence in Vidac’s innovative approach to selectively targeting the hyper-glycolysis (“Warburg Effect”) characteristic of cancer cells, caused by aberrant mitochondrial functions. Vidac Pharma’s strategy is designed to re-open the VDAC1 channel, restoring the natural apoptosis (programmed cell death) signal that is blocked by excessive HK2 activity, and reducing high lactate production in the tumor microenvironment.
In reaffirming its recommendation, Sphene highlighted Vidac Pharma’s differentiated position within oncology drug development and the potential of its clinical pipeline to address significant unmet medical needs.
The importance of targeting cell metabolism in cancer continues to gain attention in both the scientific and financial communities. A recent article in news.financial reviewed new findings in this field and cited Roche, Novartis, and Vidac Pharma, through its mitochondrial-centered approach, as companies advancing work in this area. In addition, academic research such as the 2025 study by Lin et al. in Cancer Biology & Medicine underscores the therapeutic potential of interventions focused on mitochondrial function in cancer treatment.
Dr. Max Herzberg, CEO of Vidac Pharma, stated:
“We welcome Sphene Equity Research’s continued endorsement of our strategy and pipeline. Vidac is committed to advancing breakthrough therapies targeting the fundamental biology of cancer, and we are pleased to see growing recognition of cell metabolism as a key therapeutic frontier.”
The full updated report by Sphene Equity Research, dated August 22, 2025, is available here
For more information please contact:
Vidac Pharma Holding Plc
Dr Max Herzberg
20-22 Wenlock Road
London N1 7GU
United Kingdom
http://www.vidacpharma.com/
investors@vidacpharma.com
+972-54-4257381
About Vidac Pharma
Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. Vidac develops first-in-class anti-cancer drugs by modifying the hyper-glycolytic tumor microenvironment, targeting the overexpression and wrong anchoring of the Hexokinase 2 metabolic checkpoint (HK2) in cancer cells, to renormalize tumor microenvironment and selectively provoke their programmed death, without affecting surrounding normal tissue. VDA-1102, a first drug candidate of Vidac Pharma has shown to be effective against advanced Actinic Keratosis (AK), and in Cutaneous T-cell Lymphoma (CTCL) yielded a positive effect in Phase 2 trials in humans.
Important information
The information in this press release does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only. The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.